NDAORAL-21TABLET
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENOVID-E 21 is an oral contraceptive combining mestranol (estrogen) and norethynodrel (progestin), approved in 1961 as a pioneering hormonal birth control tablet. It represents a foundational product in the history of oral contraceptives, used for pregnancy prevention in women of reproductive age. The combination works by suppressing ovulation through hormonal feedback mechanisms.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling reduced team investment and focus on transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ENOVID-E 21 offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Roles on this product are primarily focused on managed decline, supply continuity, and transition planning rather than expansion or innovation.
Brand ManagerField Sales
Worked on ENOVID-E 21 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.